PMID- 29617506
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1678-9741 (Electronic)
IS  - 0102-7638 (Print)
IS  - 0102-7638 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan-Feb
TI  - Chronic Chagas Cardiomyopathy Patients and Resynchronization Therapy: a Survival 
      Analysis.
PG  - 82-88
LID - S0102-76382018000100082 [pii]
LID - 10.21470/1678-9741-2017-0134 [doi]
AB  - INTRODUCTION: Chagas disease represents an important health problem with 
      socioeconomic impacts in many Latin-American countries. It is estimated that 20% 
      to 30% of the people infected by Trypanosoma cruzi will develop chronic Chagas 
      cardiomyopathy (CCC), which is generally accompanied by heart failure (HF). 
      Cardiac resynchronization therapy (CRT) may be indicated for patients with HF and 
      electromechanical dysfunctions. OBJECTIVE: The primary endpoint of this study was 
      to analyze the response to CRT in patients with CCC, while the secondary endpoint 
      was to estimate the survival rates of CRT responder patients. METHODS: This is an 
      observational, cross-sectional and retrospective study. The records of 50 
      patients with CRT pacing devices implanted between June 2009 and March 2017 were 
      analyzed. For statistical analyses, Pearson's correlation was used along with 
      Student's t-test, and survival was analyzed using the Kaplan-Meier method. A P 
      value of <0.05 was considered significant. RESULTS: Out of 50 patients, 56% were 
      male, with a mean age of 63.4+/-13.3 years and an average CRT duration of 61.2+/-21.7 
      months. The mean QRS duration was 150.12+/-12.4 ms before and 116.04+/-2.2 ms after 
      the therapy (P<0.001). The mean left ventricular ejection fractions (LVEF) were 
      29+/-7% and 39.1+/-12.2% before and after CRT, respectively (P<0.001). A total of 35 
      (70%) patients had a reduction of at least one New York Heart Association (NYHA) 
      functional class after six months of therapy (P=0.014). The survival rate after 
      72 months was 45%. CONCLUSION: This study showed clinical improvement and a 
      nonsignificant survival rate in patients with CCC after the use of CRT.
FAU - Menezes Junior, Antonio da Silva
AU  - Menezes Junior ADS
AD  - Escola de Ciencias Medicas, Farmaceuticas e Biomedicas of the Pontificia 
      Universidade Catolica de Goias (PUC-GO), Goiania, GO, Brazil.
FAU - Lopes, Cynthia Caetano
AU  - Lopes CC
AD  - Escola de Ciencias Medicas, Farmaceuticas e Biomedicas of the Pontificia 
      Universidade Catolica de Goias (PUC-GO), Goiania, GO, Brazil.
FAU - Cavalcante, Patricia Freire
AU  - Cavalcante PF
AD  - Escola de Ciencias Medicas, Farmaceuticas e Biomedicas of the Pontificia 
      Universidade Catolica de Goias (PUC-GO), Goiania, GO, Brazil.
FAU - Martins, Edesio
AU  - Martins E
AD  - Escola de Ciencias Medicas, Farmaceuticas e Biomedicas of the Pontificia 
      Universidade Catolica de Goias (PUC-GO), Goiania, GO, Brazil.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - Brazil
TA  - Braz J Cardiovasc Surg
JT  - Brazilian journal of cardiovascular surgery
JID - 101677045
SB  - IM
MH  - Cardiac Resynchronization Therapy/*methods
MH  - Chagas Cardiomyopathy/*mortality/*therapy
MH  - Chronic Disease
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Survival Analysis
PMC - PMC5873775
COIS- No conflict of interest.
EDAT- 2018/04/05 06:00
MHDA- 2018/12/12 06:00
PMCR- 2018/01/01
CRDT- 2018/04/05 06:00
PHST- 2017/04/01 00:00 [received]
PHST- 2017/07/09 00:00 [accepted]
PHST- 2018/04/05 06:00 [entrez]
PHST- 2018/04/05 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - S0102-76382018000100082 [pii]
AID - 10.21470/1678-9741-2017-0134 [doi]
PST - ppublish
SO  - Braz J Cardiovasc Surg. 2018 Jan-Feb;33(1):82-88. doi: 
      10.21470/1678-9741-2017-0134.